- Conditions
- Adult Congenital Heart Disease, Congenital Heart Disease, Systemic Right Ventricle, Transposition of the Great Arteries, Congenitally Corrected Transposition of the Great Arteries, Fontan, Single Ventricle, Tetralogy of Fallot (TOF)
- Interventions
- SGLT2 inhibitors
- Drug
- Lead sponsor
- Leiden University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Grand Rapids, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced May 21, 2026, 7:19 PM EDT